{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:01:40Z","timestamp":1791298900307,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.diagmicrobio.2013.11.010","type":"journal-article","created":{"date-parts":[[2013,11,15]],"date-time":"2013-11-15T11:01:15Z","timestamp":1384513275000},"page":"263-267","source":"Crossref","is-referenced-by-count":49,"title":["Characterization of variables that may influence ozenoxacin in susceptibility testing, including MIC and MBC values"],"prefix":"10.1016","volume":"78","author":[{"given":"Marta","family":"Tato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuly","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Isabel","family":"Morosini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Moreno-Bofarull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Garcia-Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domingo","family":"Gargallo-Viola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Cant\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2013.11.010_bb0005","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jac\/34.2.261","article-title":"In-vitro activity of new sulphanilil fluoroquinolones against Staphylococcus aureus","volume":"34","author":"Allemandi","year":"1994","journal-title":"J. Antimicrob. Chemother"},{"key":"10.1016\/j.diagmicrobio.2013.11.010_bb0010","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2165\/00003088-200241100-00004","article-title":"Clinical role of protein binding of quinolones","volume":"41","author":"Bergogne-B\u00e9r\u00e9zin","year":"2002","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.diagmicrobio.2013.11.010_bb0015","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0732-8893(01)00338-8","article-title":"Influence of CO2 incubation on quinolone activity against Streptococcus pneumoniae and Haemophilus influenzae","volume":"42","author":"Bolmstrom","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2013.11.010_bb0020","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Development of in vitro susceptibility testing criteria and quality control parameters; approved guideline, Second Edition (M23-A3). CLSI, Wayne, PA; 2003."},{"key":"10.1016\/j.diagmicrobio.2013.11.010_bb0025","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, Ninth Edition (M07-A9). Wayne, PA: CLSI; 2012a."},{"key":"10.1016\/j.diagmicrobio.2013.11.010_bb0030","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard, Eleventh Edition (M02-A11). Wayne, PA: CLSI; 2012b."},{"key":"10.1016\/j.diagmicrobio.2013.11.010_bb0035","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement (M100-S22). Wayne, PA: CLSI; 2012c."},{"key":"10.1016\/j.diagmicrobio.2013.11.010_bb0040","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1529-8019.2012.01493.x","article-title":"Update on topical antibiotics in dermatology","volume":"25","author":"Drucker","year":"2012","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.diagmicrobio.2013.11.010_bb0045","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1128\/JCM.02464-08","article-title":"High concentrations of manganese in Mueller-Hinton agar increase MICs of tigecycline determined by Etest","volume":"47","author":"Fern\u00e1ndez-Mazarrasa","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2013.11.010_bb0050","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1128\/JCM.06686-11","article-title":"Cation concentration variability of four distinct Mueller-Hinton agar brands influences polymyxin B susceptibility results","volume":"50","author":"Girardello","year":"2012","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2013.11.010_bb0055","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1128\/AAC.01637-09","article-title":"Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates","volume":"54","author":"Higgins","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2013.11.010_bb0060","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1128\/CMR.00030-13","article-title":"A current perspective on daptomycin for the clinical microbiologist","volume":"26","author":"Humphries","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.diagmicrobio.2013.11.010_bb0065","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1128\/AAC.43.3.525","article-title":"Influences of urinary pH on ciprofloxacin pharmacokinetics in humans and antimicrobial activity in vitro versus those of sparfloxacin","volume":"43","author":"Kamberi","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2013.11.010_bb0070","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/AAC.01201-10","article-title":"Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus","volume":"55","author":"Lemaire","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2013.11.010_bb0075","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijantimicag.2011.03.002","article-title":"Activity of finafloxacin, a novel fluoroquinolone with increased activity at acid pH, towards extracellular and intracellular Staphylococcus aureus, Listeria monocytogenes and Legionella pneumophila","volume":"38","author":"Lemaire","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2013.11.010_bb0080","doi-asserted-by":"crossref","unstructured":"L\u00f3pez Y, Tato M, Espinal P, Garcia-Alonso F, Gargallo-Viola D, Cant\u00f3n R, Vila J. In vitro activity of ozenoxacin against Gram-positive bacteria susceptible and resistant to other quinolones. Antimicrob Agents Chemother 2013 Sep 30. [Epub ahead of print]","DOI":"10.1128\/AAC.01509-13"},{"key":"10.1016\/j.diagmicrobio.2013.11.010_bb0085","unstructured":"Morrissey I, Janes R, Dallow J, Leakey A, Guglietta A, Gargallo D. Ozenoxacin. Activity against gram-positive bacteria (GPB) causing skin and soft tissue infections (SSTI) collected in 2009-10. Poster session presented at: 52nd Intersci Conf Antimicrob Agents Chemother; 2012 Sep 9-12; San Francisco, CA."},{"key":"10.1016\/j.diagmicrobio.2013.11.010_bb0090","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000094670","article-title":"The pH of the skin surface and its impact on the barrier function","volume":"19","author":"Schmid-Wendtner","year":"2006","journal-title":"Skin Pharmacol Physiol"},{"key":"10.1016\/j.diagmicrobio.2013.11.010_bb0095","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000238584","article-title":"Conditions affecting the results of susceptibility testing for the quinolone compounds","volume":"34","author":"Smith","year":"1988","journal-title":"Chemotherapy"},{"issue":"Suppl 1","key":"10.1016\/j.diagmicrobio.2013.11.010_bb0100","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF01645195","article-title":"Effects of pH and magnesium on the activity of 4-quinolone antibacterials","volume":"14","author":"Smith","year":"1986","journal-title":"Infection"},{"key":"10.1016\/j.diagmicrobio.2013.11.010_bb0105","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1128\/AAC.00833-10","article-title":"In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions","volume":"55","author":"Stubbings","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2013.11.010_bb0110","doi-asserted-by":"crossref","first-page":"8407","DOI":"10.1128\/JB.186.24.8407-8423.2004","article-title":"Effect of mild acid on gene expression in Staphylococcus aureus","volume":"186","author":"Weinrick","year":"2004","journal-title":"Bacteriol"},{"key":"10.1016\/j.diagmicrobio.2013.11.010_bb0115","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1128\/CMR.2.4.378","article-title":"Fluoroquinolone antimicrobial agents","volume":"2","author":"Wolfson","year":"1989","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.diagmicrobio.2013.11.010_bb0120","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1128\/AAC.01433-10","article-title":"Protein binding: do we ever learn?","volume":"55","author":"Zeitlinger","year":"2011","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889313005956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889313005956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T23:47:58Z","timestamp":1564703278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889313005956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0732889313005956"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2013.11.010","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}